Clinical Toxicology of Novel Synthetic Opioids (Nitazenes and Emerging Fentanyl Analogues): Toxicokinetics, Toxicodynamics, Diagnosis, Management, and Public Health Challenges

Abstract

One of the most deadly and quickly developing risks in the current opioid crisis are novel synthetic opioids (NSOs), such as nitazenes and newly developed fentanyl analogues. Nitazenes were first synthesised in the 1950s but were never approved for clinical use. Since 2019, they have alarmingly reappeared in the illicit drug supply, showing pharmacological characteristics that defy traditional toxicological management paradigms and potencies that may surpass carfentanil in some analogues. Using the PubMed/MEDLINE, EMBASE, Scopus, and Web of Science databases, a thorough narrative review of peer-reviewed literature covering publications from 2015 through May 2026 was carried out. Reports from the United Nations Office on Drugs and Crime (UNODC), the Drug Enforcement Administration (DEA), the European Monitoring Center for Drugs and Drug Addiction (EMCDDA), and national public health agencies were also included. At the mu-opioid receptor (MOR), NSOs function as complete, very effective agonists. Nitazenes also show distinctively delayed receptor dissociation kinetics, which cause severe and protracted respiratory depression. Rapid hepatic metabolism by polymorphic CYP2D6 and CYP2B6 enzymes is revealed by toxicokinetic tests, with intrinsic clearance values that are on par with or higher than those of testosterone. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) continue to be the gold standards for diagnosis; traditional immunoassay-based urine drug screenings consistently fail to identify NSOs. Partial or total naloxone resistance complicates clinical therapy, requiring high cumulative doses (up to 10–20 mg) and extended observation times. NSOs provide a paradigm-shifting risk to public health infrastructure and toxicological practice. Expanding toxicological screening capabilities, modifying naloxone delivery methods, integrating harm reduction programs, and coordinating worldwide regulatory response to the constantly changing environment of new opioid analogues are all urgent issues.